Table of Contents
- Overview of Ifosfamide trials
- Cancer types being studied
- Trial phases and study designs
- Who may take part
- Main endpoints being measured
- Selected trial examples
- What these trials mean for patients
Overview of Ifosfamide trials
These studies are testing Ifosfamide in different cancer treatment plans, mostly as part of combination therapy.[1] The trial data show a wide range of goals, including finding the best dose, checking safety, and comparing how well treatment works against standard care or other regimens.[2]
Cancer types being studied
Ifosfamide is being studied in trials for Ewing sarcoma, soft tissue sarcoma, osteosarcoma, lymphoma, leukemia, germ cell tumors, neuroblastoma, and penile squamous cell carcinoma.[3] Some studies focus on newly diagnosed disease, while others include relapsed, refractory, recurrent, or high-risk disease.[4]
Trial phases and study designs
The trial set includes Phase 1, Phase 2, Phase 3, and Phase 4 studies.[5] Phase 1 trials in the data mainly look at dose-finding, safety, and tolerability, while later phases focus more on treatment benefit and comparison with standard regimens.[6]
Most of the studies are interventional, which means the research team gives a treatment and then measures the results.[7] Several trials are randomized, meaning patients are assigned by chance to different treatment groups, so the treatments can be compared fairly.[8]
Who may take part
Eligibility depends on the trial and the cancer being studied.[9] Some trials include children and adolescents, some include young adults, and some include adults only.[10]
Children and adolescents: Several leukemia, lymphoma, neuroblastoma, and sarcoma trials are designed for younger patients.[11]
Adults: Some lymphoma, sarcoma, and germ cell tumor studies are aimed at adults with relapsed, refractory, or advanced disease.[12]
High-risk disease: Many studies select patients with a higher chance of relapse or poor outcome, such as high-risk Ewing sarcoma or high-risk osteosarcoma.[6]
Relapsed or refractory disease: Some trials include people whose cancer came back or did not respond well to earlier treatment.[13]
Main endpoints being measured
The most common endpoint is event-free survival, which means the time before a cancer-related event happens, such as relapse, progression, second cancer, or death.[14] Other common endpoints are disease-free survival, overall survival, and objective response rate.[15]
Some studies also measure treatment safety, including adverse effects, serious adverse effects, and dose-limiting toxicities, which are side effects that stop a dose from being increased further.[5] In a few trials, researchers also look at special outcomes such as acute skin toxicity during radiotherapy, immune reconstitution, histological response, or complete metabolic response.[16]
Selected trial examples
In the iEuroEwing trial, researchers are studying treatment optimization for people with Ewing sarcoma, including standard-risk, high-risk, and disseminated disease groups.[1] The main goals include improving event-free survival and testing maintenance treatment added to standard chemotherapy.[1]
In the AIEOP-BFM ALL 2017 trial, children and adolescents with acute lymphoblastic leukemia are being studied in several randomized questions, including whether extra therapy can improve event-free survival or disease-free survival in different risk groups.[2] This trial also measures non-response, relapse, second malignancy, death, and in one part, immune recovery.[2]
In the rEECur trial, patients with recurrent or primary refractory Ewing sarcoma are being compared across different chemotherapy regimens to find the best balance of efficacy, toxicity, and acceptability.[4] The main endpoint is event-free survival time.[4]
In the high-risk osteosarcoma study, patients aged 2 to 50 years are being treated with post-operative chemotherapy plus mifamurtide, and the main goal is to improve event-free survival.[6] The study measures relapse, progression, second malignancy, and death as events.[6]
In several lymphoma trials, Ifosfamide is part of salvage or combination treatment for relapsed or refractory disease, with outcomes such as response rate, progression-free survival, and event-free survival.[9] These studies include both adult and pediatric populations.[9]
What these trials mean for patients
For patients, these trials are trying to answer practical questions: which treatment works best, which treatment is safer, and which treatment gives the longest control of the cancer.[17] Because the studies are different, a person may be eligible for one trial but not another based on age, diagnosis, disease risk, and how the cancer responded to earlier treatment.[18] The trial data show that Ifosfamide is mainly being used as one part of a larger cancer treatment plan, not as a stand-alone study drug.[12]
